公开(公告)号：US20230221333A1

公开(公告)日：2023-07-13

申请号：US18155299

申请日：2023-01-17

Applicant: Genentech, Inc. ,  Universiteit Utrecht Holding B.V.

Inventor： Wendy Noel Sandoval ,  Tomislav Caval ,  Albert J.R. Heck ,  Elizabeth Sara Hecht

IPC: G01N33/68

CPC classification number: G01N33/6848 ,  G01N33/6824 ,  G01N2560/00 ,  G01N2333/96466

Abstract: This disclosure relates to new methods for antibody characterization sequencing, such as middle down antibody characterization and sequencing, for example, for de novo antibody sequencing, identifying known antibodies in a sample, or verifying the sequence of antibodies in a sample. In some embodiments, the methods involve exposing antibodies to cathepsin D, cathepsin L, and/or cathepsin D and L, followed by mass spectrometry and sequence identification and deconvolution.

公开(公告)号：US20230048743A1

公开(公告)日：2023-02-16

申请号：US17811316

申请日：2022-07-08

Applicant: Genentech Inc.

Inventor： Elizabeth Sara Hecht ,  Shrenik Chetan Mehta ,  Wendy Noel Sandoval ,  Sreedhara Alavattam ,  Nathaniel Robert Tzizik-Swanson

IPC: C07K16/40 ,  C12N15/85

Abstract: The present application relates to recombinant antibodies that are engineered to alter interactions between the antibodies and one or more endogenous lipases of a host cell used to produce the antibodies. In some cases, the antibodies are mutated in the heavy chain constant region, such as at CH1, CH2, and/or CH3. In other cases, the antibodies are mutated to alter their glycosylation profile.